CRLF1 Secreted by Cardiac Fibroblasts: A New Driver and Potential Therapeutic Target for Hypertrophic Cardiomyopathy

Understanding Hypertrophic Cardiomyopathy: A Complex Genetic Puzzle

Hypertrophic cardiomyopathy (HCM) is recognized as the most common inherited cardiac disorder, affecting approximately 1 in 500 individuals worldwide. It is characterized by the unexplained thickening of the heart muscle, specifically the left ventricle and the interventricular septum. This thickening, or hypertrophy, can obstruct blood flow from the heart to the rest of the body, leading to symptoms such as chest pain, shortness of breath, palpitations, and in the most tragic cases, sudden cardiac death in young adults and athletes. For decades, the primary focus of HCM research has been on the sarcomere—the basic contractile unit of muscle cells. Mutations in genes encoding sarcomeric proteins, such as MYH7 and MYBPC3, are well-documented causes of the disease. However, a significant clinical challenge remains: nearly half of all patients diagnosed with HCM do not possess identifiable mutations in these sarcomere genes. This genetic heterogeneity suggests that other, non-genetic or secondary mechanisms must be at play, converging on a common pathway that causes the heart muscle to thicken regardless of the initial trigger. Identifying these common pathways is essential for developing universal therapies that can treat all HCM patients, not just those with specific genetic defects.

The Discovery of CRLF1: A New Player in Heart Health